Trial Profile
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary) ; Aclidinium bromide/formoterol; Beclometasone/formoterol; Budesonide/formoterol; Formoterol; Formoterol/fluticasone propionate; Formoterol/glycopyrrolate; Glycopyrrolate; Glycopyrrolate/indacaterol; Indacaterol; Mometasone/formoterol; Olodaterol/tiotropium bromide; Salmeterol; Salmeterol/fluticasone propionate; Tiotropium bromide; Umeclidinium; Umeclidinium/vilanterol; Vilanterol/fluticasone furoate
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms PASS
- Sponsors AstraZeneca
- 30 Jan 2023 Status changed from recruiting to completed.
- 19 Dec 2022 Planned End Date changed from 1 Jun 2023 to 30 Dec 2022.
- 19 Dec 2022 Planned primary completion date changed from 1 Jun 2023 to 30 Dec 2022.